Halia Therapeutics is discovering and developing a pipeline of novel therapeutics to improve patients' lives with chronic inflammatory disorders and neurodegenerative diseases, with its initial programs targeting NEK7 and LRRK2.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/31/24 | $30,000,000 | Series C |
Todd Pedersen | undisclosed |
